Objective: To evaluate the efficacy of the addition to milk, 5 min and 10 h before its consumption, of a lactase obtained from Kluyveromyces lactis in lactose malabsorbers with intolerance. Design: Double-blind, placebo-controlled, crossover study. Setting: University Hospital. Subjects: In total, 11 male and 19 female (aged from 18 to 65 y, mean age 43.3 y) lactose malabsorbers with intolerance participated. Interventions: Each patient underwent three H 2 breath tests, in a random order. We used 400 ml of cow's semiskimmed milk as substrate and a b-galactosidase obtained from K. lactis. The test A was carried out adding to the milk the enzyme (3000 UI), 10 h before its consumption; the test B was performed adding the b-galactosidase (6000 UI) 5 min before milk ingestion and the test C was made using placebo. We evaluated the maximum breath H 2 concentration, the cumulative H 2 excretion and a clinical score based on intolerance symptoms (bloating, abdominal pain, flatulence and diarrhoea). Results: Our study showed a significant reduction of the mean maximum H 2 concentration after both test A (12.0777.8 p.p.m.) and test B (13.9777.99 p.p.m.) compared with test C (51.46716.12 p.p.m.) (ANOVA F ¼ 54.33, Po0.001). Similarly, there was a significant reduction of the mean cumulative H 2 excretion after both test A (142871156 p.p.m.) and test B (17617966 p.p.m.) compared with test C (579572707 p.p.m.) (ANOVA F ¼ 31.46, Po0.001). We also observed a significant reduction of the mean clinical score after both test A (0.3670.55) and test B (0.9670.85) compared with test C (3.770.79) (ANOVA F ¼ 106.81, Po0.001). Moreover, with regard to the mean clinical score, there was a significant reduction after test A with respect to test B (Bonferroni's P ¼ 0.03). Conclusions: Our study shows that in lactose malabsorbers with intolerance, the lactase obtained from K. lactis can represent a valid therapeutic strategy, with objective and subjective efficacy and without side effects.